Recognition of the F&H motif by the Lowe syndrome protein OCRL

Nature Structural and Molecular Biology

Volumn 18, Issue 7, 2011, Pages 789-795

  Pirruccello, Michelle ^a   Swan, Laura E ^a   Folta Stogniew, Ewa ^a   De Camilli, Pietro ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RAB5; RAB PROTEIN; SYNAPTOJANIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ELECTRON SPIN RESONANCE; F AND H MOTIF; GENETIC CONSERVATION; LOWE SYNDROME; MISSENSE MUTATION; MOLECULAR RECOGNITION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BINDING SITES; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; OCULOCEREBRORENAL SYNDROME; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN FOLDING; RAB5 GTP-BINDING PROTEINS; SEQUENCE ALIGNMENT;

EID: 79960058199     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2071     Document Type: Article

References (46)

1. Attree, O. et al. The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature 358, 239-242 (1992).
2. Hoopes, R.R.J. et al. Dent disease with mutations in OCRL1. Am. J. Hum. Genet. 76, 260-267 (2005).
3. Bockenhauer, D. et al. Renal phenotype in Lowe syndrome: a selective proximal tubular dysfunction. Clin. J. Am. Soc. Nephrol. 3, 1430-1436 (2008).
4. Delleman, J.W., Bleeker-Wagemakers, E.M. & van Veelen, A.W. Opacities of the lens indicating carrier status in the oculo-cerebro-renal (Lowe) syndrome. J. Pediatr. Ophthalmol. 14, 205-212 (1977). (Pubitemid 8181545)
5. Kenworthy, L. & Charnas, L. Evidence for a discrete behavioral phenotype in the oculocerebrorenal syndrome of Lowe. Am. J. Med. Genet. 59, 283-290 (1995).
6. Schurman, S.J. & Scheinman, S.J. Inherited cerebrorenal syndromes. Nat. Rev. Nephrol. 5, 529-538 (2009).
7. Bökenkamp, A. et al. Dent-2 disease: a mild variant of Lowe syndrome. J. Pediatr. 155, 94-99 (2009).
8. Shrimpton, A.E. et al. OCRL1 mutations in Dent 2 patients suggest a mechanism for phenotypic variability. Nephron Physiol. 112, 27-36 (2009).
9. Bothwell, S.P., Farber, L.W., Hoagland, A. & Nussbaum, R.L. Species-specific difference in expression and splice-site choice in Inpp5b, an inositol polyphosphate 5-phosphatase paralogous to the enzyme deficient in Lowe syndrome. Mamm. Genome 21, 458-466 (2010).
10. Jänne, P.A. et al. Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice. J. Clin. Invest. 101, 2042-2053 (1998). (Pubitemid 28244088)
11. Dressman, M.A., Olivos-Glander, I.M., Nussbaum, R.L. & Suchy, S.F. Ocrl1, a PtdIns(4,5)P(2) 5-phosphatase, is localized to the trans-Golgi network of fibroblasts and epithelial cells. J. Histochem. Cytochem. 48, 179-190 (2000).
12. Olivos-Glander, I.M., Janne, P.A. & Nussbaum, R.L. The oculocerebrorenal syndrome gene product is a 105-kD protein localized to the Golgi complex. Am. J. Hum. Genet. 57, 817-823 (1995).
13. Suchy, S.F., Olivos-Glander, I.M. & Nussabaum, R.L. Lowe syndrome, a deficiency of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi apparatus. Hum. Mol. Genet. 4, 2245-2250 (1995).
14. Erdmann, K.S. et al. A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway. Dev. Cell 13, 377-390 (2007). (Pubitemid 47321603)
15. Mao, Y. et al. A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism. EMBO J. 28, 1831-1842 (2009).
16. Ungewickell, A., Ward, M.E., Ungewickell, E. & Majerus, P.W. The inositol polyphosphate 5-phosphatase Ocrl associates with endosomes that are partially coated with clathrin. Proc. Natl. Acad. Sci. USA 101, 13501-13506 (2004). (Pubitemid 39238432)
17. Faucherre, A. et al. Lowe syndrome protein OCRL1 interacts with Rac GTPase in the trans-Golgi network. Hum. Mol. Genet. 12, 2449-2456 (2003). (Pubitemid 37220409)
18. Fukuda, M., Kanno, E., Ishibashi, K. & Itoh, T. Large scale screening for novel rab effectors reveals unexpected broad Rab binding specificity. Mol. Cell. Proteomics 7, 1031-1042 (2008). (Pubitemid 351943951)
19. Hyvola, N. et al. Membrane targeting and activation of the Lowe syndrome protein OCRL1 by rab GTPases. EMBO J. 25, 3750-3761 (2006). (Pubitemid 44300261)
20. Swan, L.E., Tomasini, L., Pirruccello, M., Lunardi, J. & de Camilli, P. Two closely related endocytic proteins that share a common OCRL-binding motif with APPL1. Proc. Natl. Acad. Sci. USA 107, 3511-3516 (2010).
21. Noakes, C.J., Lee, G. & Lowe, M. The PH domain proteins IPIP27A and B link OCRL1 to receptor recycling in the endocytic pathway. Mol. Cell. Biol. 22, 606-623 (2011).
22. Zoncu, R. et al. A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell 136, 1110-1121 (2009).
23. Miaczynska, M. et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 116, 445-456 (2004). (Pubitemid 38366320)
24. National Human Genome Research Institute. Database of the OCRL1 Mutations Causing Lowe Syndrome (National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA, 2010). .
25. Monnier, N., Satre, V., Lerouge, E., Berthoin, F. & Lunardi, J. OCRL1 mutation analysis in French Lowe syndrome patients: implications for molecular diagnosis strategy and genetic counseling. Hum. Mutat. 16, 157-165 (2000). (Pubitemid 30604905)
26. Addis, M., Loi, M., Lepiani, C., Cau, M. & Melis, M.A. OCRL mutation analysis in Italian patients with Lowe syndrome. Hum. Mutat. 23, 524-525 (2004).
27. McCrea, H.J. et al. All known patient mutations in the ASH-RhoGAP domains of OCRL affect targeting and APPL1 binding. Biochem. Biophys. Res. Commun. 369, 493-499 (2008).
28. Hichri, H. et al. From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum. Mutat. 32, 379-388 (2010).
29. Yuksel, A., Karaca, E. & Albayram, M.S. Magnetic resonance imaging, magnetic resonance spectroscopy, and facial dysmorphism in a case of Lowe syndrome with novel OCRL1 gene mutation. J. Child Neurol. 24, 93-96 (2009).
30. Tosetto, E. et al. Locus heterogeneity of Dent's disease: OCRL1 and TMEM27 genes in patients with no CLCN5 mutations. Pediatr. Nephrol. 24, 1967-1973 (2009).
31. Kawano, T., Indo, Y., Nakazato, H., Shimadzu, M. & Matsuda, I. Oculocerebrorenal syndrome of Lowe: three mutations in the OCRL1 gene derived from three patients with different phenotypes. Am. J. Med. Genet. 77, 348-355 (1998). (Pubitemid 28283679)
32. Lichter-Konecki, U., Farber, L.W., Cronin, J.S., Suchy, S.F. & Nussbaum, R.L. The effect of missense mutations in the RhoGAP-homology domain on ocrl1 function. Mol. Genet. Metab. 89, 121-128 (2006). (Pubitemid 44205468)
33. Lin, T. et al. Spectrum of mutations in the OCRL1 gene in the Lowe oculocerebrorenal syndrome. Am. J. Hum. Genet. 60, 1384-1388 (1997). (Pubitemid 27258070)
34. Holm, L. & Rosenstrom, P. Dali server: conservation mapping in 3D. Nucleic Acids Res. 38 (Suppl.), W545-W549 (2010).
35. Kaiser, S.E. et al. Structural basis of FFAT motif-mediated ER targeting. Structure 13, 1035-1045 (2005). (Pubitemid 40943334)
36. Gant-Branum, R.L., Broussard, J.A., Mahsut, A., Webb, D.J. & McLean, J.A. Identification of phosphorylation sites within the signaling adaptor APPL1 by mass spectrometry. J. Proteome Res. 9, 1541-1548 (2010).
37. Wenk, M.R. et al. Phosphoinositide profiling in complex lipid mixtures using electrospray ionization mass spectrometry. Nat. Biotechnol. 21, 813-817 (2003). (Pubitemid 36791402)
38. Zhu, G. et al. Structure of the APPL1 BAR-PH domain and characterization of its interaction with Rab5. EMBO J. 26, 3484-3493 (2007). (Pubitemid 47123536)
39. Ponting, C.P. A novel domain suggests a ciliary function for ASPM, a brain size determining gene. Bioinformatics 22, 1031-1035 (2006).
40. Nassar, N., Hoffman, G.R., Manor, D., Clardy, J.C. & Cerione, R.A. Structures of Cdc42 bound to the active and catalytically compromised forms of Cdc42GAP. Nat. Struct. Biol. 5, 1047-1052 (1998). (Pubitemid 28546267)
41. Hou, X. et al. A structural basis for Lowe syndrome caused by mutations in the Rab-binding domain of OCRL1. EMBO J. 30, 1659-1670 (2011).
42. Deprez, C. et al. Solution structure of the E. coli TolA C-terminal domain reveals conformational changes upon binding to the phage g3p N-terminal domain. J. Mol. Biol. 346, 1047-1057 (2005). (Pubitemid 40215529)
43. Painter, J. & Merritt, E.A. TLSMDweb server for the generation of multi-group TLS models. J. Appl. Cryst. 39, 109-111 (2006).
44. Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
45. Davis, I.W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).
46. Christoforidis, S. & Zerial, M. Purification and identification of novel Rab effectors using affinity chromatography. Methods 20, 403-410 (2000). (Pubitemid 32906723)